IL18 and neoplasm: Furthermore, combined gene therapy with interleukin 18 (IL-18) gene and HSV1-tk under hTERT promoter transcriptional control has been carried out, this strategy confers a specific anti-tumor immunity, partially or completely eliminating tumors (69).